Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by DONNELLY, S.
Right arrow Articles by DOYLE, D. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DONNELLY, S.
Right arrow Articles by DOYLE, D. V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1993 British Society for Rheumatology

case-report

SYSTEMIC LUPUS ERYTHEMATOSUS-LIKE SYNDROME WITH FOCAL PROLIFERATIVE GLOMERULONEPHRITIS DURING D-PENICILLAMINE THERAPY

S. DONNELLY*,, D. A. LEVISON{dagger} and D. V. DOYLE{ddagger}

*Departments of Rheumatology, St Bartholomew's Hospital London EC1
{dagger}Department of Histopathology UMDS, Guy's Campus
{ddagger}Department of Rheumatology, Whipps Cross Hospital London

Correspondence to: Correspondence to S. Donnelly

We report a patient with RA who developed serological evidence for lupus disease in the presence of a crescentic immune complex glomerulonephritis (GN). This occurred after 4 years therapy with penicillamine and resolved on withdrawal of this drug and following treatment with cyclophosphamide.

KEY WORDS: Rheumatoid arthritis, Immune complex nephritis, Cyclophosphamide


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.